Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q2 FY2020 Earnings Presentation
13 slides from Alkem Laboratories's earnings presentation, Nov 11, 2019
Slide 1: Investor Presentation Q2FY20 – November 11, 2019
Investor Presentation Q2FY20 – November 11, 2019
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Highlights of Q2FY20 and H1FY20
Key Highlights of Q2FY20 and H1FY20 • Revenue from Operations grew by 18.0% YoY during the quarter, accompanied by 100 bps YoY improvement in EBITDA margin • Profit After Tax for the quarter grew by 45.7% compared to the previous year • India Business: As per secondary sales data by IQVIA, the Compa
Slide 4: Key Financial Highlights – Q2FY20 (Consolidated)
Key Financial Highlights – Q2FY20 (Consolidated) All figures in Rs mn Revenue from Operations India sales 15,503 22,640 13,184 19,189 Q2FY19 Q2FY20 International sales 6,691 5,809 Q2FY19 Q2FY20 Q2FY19 Q2FY20
Slide 5: Key Financial Highlights – Q2FY20 (Consolidated)
Key Financial Highlights – Q2FY20 (Consolidated) All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 13,597 4,526 11,779 3,637 61.4% 60.1% 19.0% 20.0% Q2FY19 Q2FY20 Q2FY19 Q2FY20 PBT (before Minority Interest) PAT (after Minority Interest) 3,709 4,099 3,260 2,545 Q2FY19 Q2FY2
Slide 6: Key Financial Highlights – H1FY20 (Consolidated)
Key Financial Highlights – H1FY20 (Consolidated) Particulars (Rs mn) H1FY20 H1FY19 YoY growth Revenue from Operations 41,135 35,778 15.0% Gross Profit 24,974 22,064 13.2% Gross Profit margin 60.7% 61.7% EBITDA 7,171 5,674 26.4% EBITDA margin 17.4% 15.9% PBT 6,199 4,978 24.5% PBT margin 15.1% 13.9% P
Slide 7: India Business
India Business India Business: Q2FY20 Sales of Rs.15,503 million (17.6% YoY growth) • India sales contributed 69.9% to total sales in Q2FY20 • In Q2FY20, Company’s secondary sales grew by 23.5% YoY - significantly ahead of the IPM growth of 13.1% YoY. Similarly in H1FY20 also, the Company grew ahead
Slide 8: India Business – Secondary Sales Performance
India Business – Secondary Sales Performance Outperformance across most of the major therapeutic areas in Q2FY20 Established therapeutic Market rank 1 3 3 4 areas of Alkem 30.8% 29.0% 19.9% 17.5% 17.1% 12.1% 15.2% 13.3% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrient
Slide 9: US Business
US Business US Business: Q2FY20 Sales of Rs.5,276 million (11.7% growth YoY) • US sales contributed 23.8% to total sales in Q2FY20 • In Q2FY20, the Company filed 5 ANDAs with the US FDA and received 7 approvals (including 2 tentative approval) • As on September 30, 2019, the Company has filed a tota
Slide 10: Update on the US FDA inspection
Update on the US FDA inspection Facility Scope Last inspection Status post last inspection Baddi (India) Formulation August 2019 Successfully closed without any observations Daman (India) Formulation August 2019 EIR# received in October 2019, thereby successfully closing the inspection St. Louis (US
Slide 11: Other International Business
Other International Business Other International Business: Q2FY20 Sales of Rs.1,415 million (30.6% growth YoY) • Other International Market sales contributed 6.4% to total sales in Q2FY20 • The Company has presence in Australia, Europe, South East Asia, Latin America and Africa • Australia, Chile, K
Slide 12: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on September 30, 2019 Non-Institution, 19.86% Institution, 14.10% Promoter & Promoter Group, 66.04% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other
Slide 13: Thank You
Thank You